Search

Editorial Feature:

AMD/DME Case Files: Real-World Patient Profiles

Editorially Independent content supported with advertising by Genentech

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

Show Description +

When a patient reaches a limit in their treat-and-extend regimen, could switching to another extended-duration treatment help them break through to a longer duration? Ash Abbey, MD, shares a case from his clinic in which a patient with wet AMD who achieved modest interval extensions with faricimab (Vabysmo, Genentech/Roche) and was switched to high-dose aflibercept (Eylea HD, Regeneron) in hopes of achieving a longer treatment interval.

Posted: 8/30/2024

Keywords:

aflibercept

•

faricimab

•

wet AMD

•

Season Three

Up Next

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Switch Case: 66-Year-Old Man With Wet AMD

Switch Case: 66-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Potential Switch Case: 81-Year-Old Man With Wet AMD

Potential Switch Case: 81-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Switch Case: Massive PED (Part 1)

Switch Case: Massive PED (Part 1)

Yasha S. Modi, MD

Switch Case: Massive PED (Part 2)

Switch Case: Massive PED (Part 2)

Yasha S. Modi, MD

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Joseph M. Coney, MD

Treatment-Naïve Case: DME in a 54-Year-Old-Patient With Undiagnosed Diabetes

Treatment-Naïve Case: DME in a 54-Year-Old-Patient With Undiagnosed Diabetes

Joseph M. Coney, MD

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

Real-World Step Therapy Case: A Challenging DME Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Difficult-to-Treat Fluid DME Case Study

Real-World Switch Case: Difficult-to-Treat Fluid DME Case Study

Ferhina Ali, MD

Real-World Step Therapy: Suboptimal Response in Wet AMD

Real-World Step Therapy: Suboptimal Response in Wet AMD

Scott Walter, MD, MSc

Real-World Treatment-Naïve Case: Bilateral Advanced DME Treated with Two Different Agents

Real-World Treatment-Naïve Case: Bilateral Advanced DME Treated with Two Different Agents

Scott Walter, MD, MSc

Switch Case: Potential Response to Ang-2 in Wet AMD

Switch Case: Potential Response to Ang-2 in Wet AMD

Ash Abbey, MD

Back to All Videos

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

When a patient reaches a limit in their treat-and-extend regimen, could switching to another extended-duration treatment help them break through to a longer duration? Ash Abbey, MD, shares a case from his clinic in which a patient with wet AMD who achieved modest interval extensions with faricimab (Vabysmo, Genentech/Roche) and was switched to high-dose aflibercept (Eylea HD, Regeneron) in hopes of achieving a longer treatment interval.

Posted: 8/30/2024

Keywords:

aflibercept

•

faricimab

•

wet AMD

•

Season Three

Please log in to leave a comment.